These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37803333)

  • 1. Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
    Vincent CA; Nissen I; Dakhel S; Hörnblad A; Remeseiro S
    BMC Cancer; 2023 Oct; 23(1):945. PubMed ID: 37803333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
    Bassi R; Dei Cas M; Tringali C; Compostella F; Paroni R; Giussani P
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    Li L; Huang Y; Gao Y; Shi T; Xu Y; Li H; Hyytiäinen M; Keski-Oja J; Jiang Q; Hu Y; Du Z
    BMC Cancer; 2018 Dec; 18(1):1215. PubMed ID: 30514230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion.
    Ding Z; Roos A; Kloss J; Dhruv H; Peng S; Pirrotte P; Eschbacher JM; Tran NL; Loftus JC
    Mol Cancer Res; 2018 Feb; 16(2):322-332. PubMed ID: 29117939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
    Areeb Z; Stuart SF; West AJ; Gomez J; Nguyen HPT; Paradiso L; Zulkifli A; Jones J; Kaye AH; Morokoff AP; Luwor RB
    Sci Rep; 2020 Oct; 10(1):17768. PubMed ID: 33082482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
    Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
    Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells.
    Vidomanova E; Majercikova Z; Dibdiakova K; Pilchova I; Racay P; Hatok J
    Bratisl Lek Listy; 2022; 123(4):236-243. PubMed ID: 35294208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
    She L; Gong X; Su L; Liu C
    Oncologist; 2023 Jan; 28(1):e45-e53. PubMed ID: 36181764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
    Reinhardt LS; Morás AM; Henn JG; Arantes PR; Ferro MB; Braganhol E; de Souza PO; de Oliveira Merib J; Borges GR; Dalanhol CS; de Barros Dias MCH; Nugent M; Moura DJ
    Int J Pharm; 2022 Apr; 617():121584. PubMed ID: 35202726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.
    Cui X; Zhao J; Li G; Yang C; Yang S; Zhan Q; Zhou J; Wang Y; Xiao M; Hong B; Yi K; Tong F; Tan Y; Wang H; Wang Q; Jiang T; Fang C; Kang C
    Cancer Commun (Lond); 2023 Dec; 43(12):1326-1353. PubMed ID: 37920878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
    Banstola A; Duwa R; Emami F; Jeong JH; Yook S
    Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
    Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
    Munoz JL; Rodriguez-Cruz V; Greco SJ; Ramkissoon SH; Ligon KL; Rameshwar P
    Cell Death Dis; 2014 Mar; 5(3):e1145. PubMed ID: 24675463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.